



About reMYND

reMYND, founded in 2002 as a spin-off from the K.U.Leuven, drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders through two independently managed business units:

- The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as tau for Alzheimer's disease, α -synuclein for Parkinson's disease, and IAPP-toxicity for Diabetes.
- The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND's proprietary Alzheimer mouse models.

ACTIVITY:

Drive the development of disease modifying treatments for Alzheimer's disease, Parkinson's disease and diabetes

MANAGEMENT:

- Koen De Witte, M.Sc., MBA, Managing Director
- Gerard Griffioen, Ph.D., CSO DDD
- An Tanghe, Ph.D., Manager CRO
- Hans van der Saag, CFO and Legal Counsel

EMPLOYEES:

26 in Leuven, 4 in Poland

CONTACT DETAILS:

reMYND NV
Gaston Geenslaan 1
B-3001 Leuven (Heverlee)
Belgium
T: (+32) 16 75 14 20
F: (+32) 16 75 14 21
remynd@remynd.com

Drug Discovery and Development

reMYND's DDD unit aims to discover and develop disease-modifying drugs for the treatment of patients suffering from protein-misfolding disorders comprising different disease areas such as Alzheimer's disease (AD), Parkinson's disease (PD) and diabetes.

reMYND's treatments aim to decelerate – or even stop – the cellular degeneration in patients. As such, reMYND responds to a clear unmet medical need, as all marketed treatments and the majority of the products under development world-wide are aimed to only mitigate symptoms in the respective disorders. Our current lead compounds in PD and AD even completely inhibit the progression in the relevant animal models, and similar results have been found for the lead diabetes compound in a cellular assay.

At the heart of our drug discovery platform are functional screens, recapitulating noxious properties of pathological protein aggregation. Candidate drugs are extensively characterised in-vivo using our internal collection of proprietary transgenic mouse models.


In 2010, reMYND has entered into a strategic collaboration with Roche on a selection of reMYND's PD and AD products with the aim to bring at least one new treatment in Parkinson's and one new treatment for Alzheimer's to the market.





COMPANY HIGHLIGHTS:

- Leading, biology-driven discovery and development of disease modifying treatments
- Focus on protein-misfolding disorders such as Alzheimer's disease, Parkinson's disease and diabetes
- Platform readily applicable to other protein misfolding diseases, such as Huntington or ALS
- Contract Research for 3rd parties in proprietary, validated Alzheimer animal models
- Extensive network of academic, clinical and industrial collaborations



Contract Research

Current drug development requires extensive characterization of many compounds and their detailed preclinical analysis. Transgenic mouse models of Alzheimer's disease have proven valuable tools in the search for treatments that can slow down development of AD or eventually cure this devastating disorder.

reMYND's CRO is a trusted partner to help our clients understand as fast as possible the therapeutic in-vivo effects of all types of experimental AD treatments. Our mission is to help our clients identify the most promising set-up to assess potential treatment effects by contributing our extensive expertise.

Collaborations

reMYND works together with 10 scientific and clinical key opinion leaders, as well in Europe as in the US. Over the last 3 years, reMYND has signed research agreements with more than 20 biotech or pharma companies and 6 academic institutes located in the US, Europe or Japan.

